Literature DB >> 7482400

Marked increase of activated factor VII in uremic patients.

K Kario1, T Matsuo, M Matsuo, M Koide, T Yamada, S Nakamura, T Sakata, H Kato, T Miyata.   

Abstract

We investigated plasma activated factor VII (FVIIa) levels in uremic patients (nondialysis group: n = 38; dialysis group: n = 36) and healthy controls (n = 32). We also measured the plasma levels of thrombomodulin (an indicator of endothelial cell injury) and tissue factor. Plasma FVIIa showed a marked increase in the nondialysis group (mean [95% confidence interval]: 4.6 [4.1-5.1] ng/ml, p < 0.0001) with the progressive impairment of renal function, as indicated by the serum creatinine level, when compared with the 32 controls (2.8 [2.5-3.1] ng/ml), and was further increased in the dialysis group (6.1 [5.5-6.8] ng/ml, p < 0.001 vs. nondialysis group). Plasma levels of thrombomodulin and tissue factor were also higher in the nondialysis group than the control group, and were further increased in the dialysis group. Plasma tissue factor levels did not show any correlation with FVIIa or thrombomodulin in both the nondialysis and dialysis groups. Thus, circulating tissue factor appears to be released by a different mechanism from thrombomodulin and may not contribute to the direct activation of factor VII in uremic patients. On the other hand, the plasma level of thrombomodulin was positively correlated with that of FVIIa in the nondialysis group, and this correlation was independent of renal function. Thus, enhanced conversion of factor VII zymogen to FVIIa, probably related to endothelial cell injury, may be a risk factor for cardiovascular events in uremic patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7482400

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Nattokinase-heparin exhibits beneficial efficacy and safety-an optimal strategy for CKD patients on hemodialysis.

Authors:  Hao Wu; Huan Wang; Wei Li; Chi Zhang; Yushan Liu; Feng Xu; Jiepeng Chen; Lili Duan; Fengjiao Zhang
Journal:  Glycoconj J       Date:  2019-02-20       Impact factor: 2.916

2.  Clot Structure: A Potent Mortality Risk Factor in Patients on Hemodialysis.

Authors:  Katharina Schuett; Anna Savvaidis; Sebastian Maxeiner; Katharina Lysaja; Vera Jankowski; Stephan H Schirmer; Nada Dimkovic; Peter Boor; Nadine Kaesler; Friedo W Dekker; Jürgen Floege; Nikolaus Marx; Georg Schlieper
Journal:  J Am Soc Nephrol       Date:  2017-01-05       Impact factor: 10.121

Review 3.  How it all starts: Initiation of the clotting cascade.

Authors:  Stephanie A Smith; Richard J Travers; James H Morrissey
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-05-28       Impact factor: 8.250

4.  Monocyte expression of tissue factor and adhesion molecules: the link with accelerated coronary artery disease in patients with chronic renal failure.

Authors:  N M Al-Saady; E W Leatham; S Gupta; J T Kwan; J B Eastwood; C A Seymour
Journal:  Heart       Date:  1999-02       Impact factor: 5.994

5.  Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor.

Authors:  Vipul C Chitalia; Sowmya Shivanna; Jordi Martorell; Mercedes Balcells; Irene Bosch; Kumaran Kolandaivelu; Elazer R Edelman
Journal:  Circulation       Date:  2012-12-25       Impact factor: 29.690

6.  Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis.

Authors:  Yuya Horinouchi; Yasumasa Ikeda; Keijo Fukushima; Masaki Imanishi; Hirofumi Hamano; Yuki Izawa-Ishizawa; Yoshito Zamami; Kenshi Takechi; Licht Miyamoto; Hiromichi Fujino; Keisuke Ishizawa; Koichiro Tsuchiya; Toshiaki Tamaki
Journal:  Sci Rep       Date:  2018-07-18       Impact factor: 4.379

7.  Blood coagulation system in patients with chronic kidney disease: a prospective observational study.

Authors:  Meng-Jie Huang; Ri-Bao Wei; Yang Wang; Ting-Yu Su; Ping Di; Qing-Ping Li; Xi Yang; Ping Li; Xiang-Mei Chen
Journal:  BMJ Open       Date:  2017-06-01       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.